Osseointegration is a process in which a bone anchorage is used on an implant surface which provides a basis to support a prosthesis till that part of the body becomes stronger and supports firmly. These implants are used in various applications such as dental implants, bone and joint replacement procedures, and implants undertaken for amputees. The osseointegration implants are made from material such as titanium, zirconia, ceramic, stainless steel, and others.
The global osseointegration implants market is estimated to be valued at US$ 7,558.90 million in 2022 and is expected to exhibit a CAGR of 6.3% during the forecast period (2022-2030).
Figure 1. Global Osseointegration Implants Market Share (%), by Product Type, 2022
Growing number of joint replacement surgeries among geriatric population is expected to drive the osseointegration implants market growth
Increasing patient population undergoing joint replacement surgeries has boosted growth of the global osseointegration implants market. For instance, in June 2019, according to the data published by the National Center for Biotechnology Information, approximately 40 percent of the global population over age 55 experiences chronic knee pain, of those, 50.8 million suffer from disabling pain, and about 2.6 million turn to knee replacement surgery each year. Approximately 0.8 percent of Americans are living with a hip replacement, and 1.5 percent with a knee replacement. More women are living with prosthetic hips and knees than men. The survey included 18 countries with a total population of 755 million, and an estimated 1,324,000 annual primary and revision total knee procedures. According to the National Joint Registry (NJR), in 2017, around 992,090 primary total hip replacements, 1,087,611 knee replacements, 4,687 ankle replacements, 30,720 shoulder replacements, and 2,872 elbow replacements were performed in the U.K. Moreover, in the U.S, around 17,500 new Spinal Cord Injury (SCI) cases were performed annually and an estimated 285,000 people were suffering from SCI in 2017, as per National Spinal Cord Injury Statistical Center (NSCISC).
|Base Year:||2021||Market Size in 2022:||US$ 7,558.90 Mn|
|Historical Data for:||2017 to 2021||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||6.3%||2030 Value Projection:||US$ 12,313.46 Mn|
Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, and Sun Pharmaceutical Industries Ltd.
|Restraints & Challenges:||
Figure 2. Global Osseointegration Implants Market Share (%), by Region, 2022
Increasing demand for cosmetic dentistry is expected to drive the global osseointegration implants market over the forecast period
Increasing demand for cosmetic dentistry, owing to rising prevalence of dental decays is supporting growth of the global osseointegration implants market. For instance, in March 2022, according to the World Health Organization, it is estimated that oral diseases affect nearly 3.5 million people globally. According to the WHO, 60–90% of children are affected by dental caries. Untreated dental caries (tooth decay) in permanent teeth is the most common health condition according to the Global Burden of Disease 2019. According to the U.S. Department of Health and Human Services, in 2018, the prevalence of total dental caries among the age group aged 2–19 years was 45.8% and it increases with age, from 21.4% (among age group 2–5) to 50.5% (among age group 6–11) and 53.8% (among age group 12–19) in 2016. Moreover, growing disposable incomes in various countries has also influenced growth of the osseointegration implants market.
Global Osseointegration Implants Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, medical devices, etc., by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.
However, the COVID-19 pandemic had a negative impact on the global osseointegration implants market, owing to the decrease in number of osseointegration surgeries. For instance, in May 2020, according to the National Center for Biotechnology Information, surgical practices had been significantly impacted with all specialties writing guidelines for how to manage during this crisis. The surgeons were busy in helping the other doctors during the coronavirus pandemic time period. The main focus was to treat the COVID patients with correct medication treatment and prevent spreading of the coronavirus. The COVID 19 pandemic put restriction on the dental implant surgeries and other osseointegration surgeries to avoid the spread of coronavirus disease among the surgeons, patients and the corona infected patients within the clinics and hospitals.
Global Osseointegration Implants Market: Key Developments
In February 2022, Zimmer Biomet Holdings, Inc., medical device company, announce the launch in North American and European launch of OverdenSURE, a new overdenture attachment system for Zimmer Biomet dental implants. This new product line features a zirconium nitride abutment coating for aesthetics and function, and a wider range of abutment sizes for increased restorative flexibility — all wrapped in a classic system design that is intuitive to the user.
Global Osseointegration Implants Market: Restraint
The major factors that hinder growth of the global osseointegration implants market include high-cost associated with the implants or surgery and risk and complications associated with osseointegration surgery. Although, demand for osseointegration implants is increasing worldwide, high-cost associated with the implants or surgery with inadequate reimbursement coverage has restrained growth of the osseointegration implants market. In Australia, the surgical procedure to insert the implant is not covered by the Medicare system and is paid through self-funding or by an individual’s Private Health Insurance as per the Australian Orthotic Prosthetic Association. Moreover, risk and complications associated with osseointegration surgery is one of the major factor hampering growth of the market. Some of major risk and complications associated with osseointegration implants includes irritation of the soft tissues in the skin-penetration area and post-surgical infections. The failure of the treatment might result in re-amputation at a higher level or reverting to a conventional prosthesis.
Major players operating in the global osseointegration implants market include DENTSPLY Sirona, Danaher Corporation, Camlog, Osstem Implant, Medtronic, Stryker Corporation, Zimmer Biomet Holdings, Smith and Nephew Plc., Straumann AG Group, Integrum SE, ConMed Corporation, Southern Implants.
Osseointegration is defined as a direct bone anchorage to an implant surface which can provide a basis to support a prosthesis till it becomes stronger and supports firmly. Osseointegration implants is a type of implant that contains pores in which osteoblasts and cells containing connective tissue can migrate freely. Osseointegration implants are used for various applications in the field of dental implants, bone and joint replacement procedures, and implants undertaken for providing better quality of life to the amputees. It is a widely accepted implant procedure in the health care industry at present. Some of the factors that impact attachment of the bone to the metal surface include biocompatibility of the implant material, nature of the implant, surgical technique involved, and recovery time for healing.
Key players are opting for growth strategies such as new product launch, acquisitions, partnerships, joint ventures, and agreements to increase their foothold in this market. For instance, in April 2018, Integrum SE, provides innovative systems for bone-anchored prostheses launched a new revolutionary OPRA implant system, which will be initially available only in London and would be distributed through London International Patient Services (LIPS) - an organization seeking treatment for international patients. Moreover, in December 2021, Koninklijke Philips N.V., a multinational conglomerate company acquired Vesper Medical Inc., a U.S.-based medical technology company that develops minimally-invasive peripheral vascular devices. Through this acquisition, Vesper Medical will expand Philips’ portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.